AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Schneider
F
F
Bohlander
S K
SK
Schneider
S
S
Papadaki
C
C
Kakadyia
P
P
Dufour
A
A
Vempati
S
S
Unterhalt
M
M
Feuring-Buske
M
M
Buske
C
C
Braess
J
J
Wandt
H
H
Hiddemann
W
W
Spiekermann
K
K
D050676:Core Binding Factor Alpha 2 Subunit / Q000502:physiology*; D003593:Cytoplasm / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000502:physiology*; D018450:Disease Progression; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053614:Janus Kinase 2 / Q000502:physiology*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D008957:Models, Genetic; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000378:metabolism / Q000473:pathology*; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D000075142:RUNX1 Translocation Partner 1 Protein; D014157:Transcription Factors / Q000378:metabolism / Q000502:physiology*
D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; C493728:RUNX1 protein, human; C082222:RUNX1T1 protein, human; D014157:Transcription Factors; C507924:JAK2 protein, human; D053614:Janus Kinase 2